Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer

Table 4

Summary of pathways returned by REACTOME using DAVID for early- and late-stage NSCLC.

Early-stage NSCLC
Term	Count	%	value
Hemostasis	6	27.3
Signaling in immune system	6	27.3
Integrin cell surface interactions	3	13.6	0.0223
Metabolism of carbohydrates	3	13.6	0.0295
Late-stage NSCLC
Term	Count	%	value
Cell cycle, mitotic	21	34.4
Cell cycle checkpoints	10	16.4
Cdc20: phospho-APC/C-mediated degradation of cyclin A	6	9.8
APC-Cdc20-mediated degradation of Nek2A	4	6.6	0.00211
DNA replication	5	8.2	0.0239